<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02820987</url>
  </required_header>
  <id_info>
    <org_study_id>15/493</org_study_id>
    <nct_id>NCT02820987</nct_id>
  </id_info>
  <brief_title>PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock</brief_title>
  <acronym>PAACS</acronym>
  <official_title>Pharmacokinetics and Pharmacodynamic (PK/PD) of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates PK/PD of an extended-infusion protocol of meropenem,
      piperacillin-tazobactam and cefepime, in the early phase of septic shock.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Beta Lactams are the keystones of shock septic treatment. Early phase of septic shock is a
      period of disturbed pharmacokinetics, with augmented renal clearance and distribution volume
      of hydrophilic drugs as Beta Lactams. Consequently, early phase of septic shock is a period
      at risk of underdosing Beta Lactam, which could increase the risk of clinical failure an
      mortality.

      Data are available concerning underdosing of MEROPENEM, PIPERACILLIN-TAZOBACTAM and CEFEPIME,
      when administered in bolus.

      No data exist concerning the achievement of a target of 100% of the whole interval above 4
      time the superior breakpoint of Pseudomonas Aeruginosa according to EUCAST (European
      Committee on Antimicrobial Susceptibility Testing), during the 48 first hours of treatment of
      septic shock, when Beta Lactam are administered in extended infusion.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving the PK/PD target</measure>
    <time_frame>First 48 hours</time_frame>
    <description>Proportion of patients achieving the target of 100% of 48 first hours of treatment above 4 time the upper critical breakpoint for Pseudomonas Aeruginosa</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>28th day</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">129</enrollment>
  <condition>Septic Shock</condition>
  <arm_group>
    <arm_group_label>MEROPENEM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After enrollment, patients of MEROPENEM arm will receive an initial 2g bolus of MEROPENEM and 2g infusion over 3 hours every eight hours, during 48 hours, without modification of rhythm and dose according to renal function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PIPERACILLIN-TAZOBACTAM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After enrollment, patients of PIPERACILLIN - TAZOBACTAM arm will receive an initial 4g bolus of PIPERACILLIN - TAZOBACTAM and a 16g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CEFEPIME</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>After enrollment, patients of CEFEPIME arm will receive an initial 2g bolus of CEFEPIME and a 6g continuous infusion per day, during 48 hours, without modification of rhythm and dose according to renal function.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEROPENEM</intervention_name>
    <description>Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.</description>
    <arm_group_label>MEROPENEM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PIPERACILLIN-TAZOBACTAM</intervention_name>
    <description>Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.</description>
    <arm_group_label>PIPERACILLIN-TAZOBACTAM</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CEFEPIME</intervention_name>
    <description>Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.</description>
    <arm_group_label>CEFEPIME</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Septic shock

          -  Meropenem, piperacillin-tazobactam or cefepime started after enrollment

        Exclusion Criteria:

          -  Pregnancy

          -  Central nervous system infection

          -  Burns
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>NAVELLOU Jean Christophe, MD</last_name>
    <email>jcnavellou@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>WINISZEWSKI Hadrien, Resident</last_name>
    <email>hadrien51@hotmail.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Taccone FS, Laterre PF, Dugernier T, Spapen H, Delattre I, Wittebole X, De Backer D, Layeux B, Wallemacq P, Vincent JL, Jacobs F. Insufficient Î²-lactam concentrations in the early phase of severe sepsis and septic shock. Crit Care. 2010;14(4):R126. doi: 10.1186/cc9091. Epub 2010 Jul 1.</citation>
    <PMID>20594297</PMID>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2016</study_first_submitted>
  <study_first_submitted_qc>June 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 1, 2016</study_first_posted>
  <last_update_submitted>July 1, 2016</last_update_submitted>
  <last_update_submitted_qc>July 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Septic shock, Beta Lactams, Extended infusion, PK/PD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Septic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meropenem</mesh_term>
    <mesh_term>Thienamycins</mesh_term>
    <mesh_term>Tazobactam</mesh_term>
    <mesh_term>Penicillanic Acid</mesh_term>
    <mesh_term>Piperacillin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
    <mesh_term>Cephalosporins</mesh_term>
    <mesh_term>Piperacillin, tazobactam drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

